Key Points
- Insider sale: Director David Raben sold 5,500 shares on April 27 at an average price of $22.88 for $125,840, reducing his holdings by 9.05% to 55,286 shares; the trade was executed under a pre-arranged Rule 10b5-1 plan (he also sold ~16,500 shares in early March).
- Market context: BCAX opened at $21.92 with a market cap of $1.44 billion and a 52-week range of $7.80 to $24.25, trading above its 50‑day and 200‑day moving averages ($19.82 and $17.84).
- Analyst view: Street sentiment is a consensus "Moderate Buy" with an average price target of $28, based on eight Buy, three Hold and one Sell ratings and several recent upward target revisions.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) insider David Raben sold 5,500 shares of Bicara Therapeutics stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $22.88, for a total transaction of $125,840.00. Following the completion of the transaction, the insider directly owned 55,286 shares of the company's stock, valued at $1,264,943.68. This trade represents a 9.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Raben also recently made the following trade(s):
- On Tuesday, March 3rd, David Raben sold 200 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.45, for a total transaction of $3,690.00.
- On Wednesday, March 4th, David Raben sold 16,300 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.52, for a total transaction of $301,876.00.
Bicara Therapeutics Stock Performance
Shares of Bicara Therapeutics stock opened at $21.92 on Wednesday. The stock has a market capitalization of $1.44 billion, a PE ratio of -8.66 and a beta of -1.23. Bicara Therapeutics Inc. has a 52-week low of $7.80 and a 52-week high of $24.25. The company has a 50-day simple moving average of $19.82 and a two-hundred day simple moving average of $17.84.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its earnings results on Monday, March 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.04. As a group, equities research analysts forecast that Bicara Therapeutics Inc. will post -2.72 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of analysts have recently commented on BCAX shares. BTIG Research reiterated a "buy" rating on shares of Bicara Therapeutics in a research note on Thursday, January 15th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Bicara Therapeutics in a research note on Wednesday, April 8th. Wells Fargo & Company lifted their price target on shares of Bicara Therapeutics from $11.00 to $16.00 and gave the stock an "equal weight" rating in a research note on Tuesday, March 31st. HC Wainwright lifted their price target on shares of Bicara Therapeutics from $40.00 to $42.00 and gave the stock a "buy" rating in a research note on Tuesday, March 31st. Finally, Wedbush reiterated an "outperform" rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research note on Tuesday, March 31st. Eight analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, Bicara Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $28.00.
Read Our Latest Analysis on BCAX
Hedge Funds Weigh In On Bicara Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in BCAX. Legal & General Group Plc boosted its holdings in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock worth $29,000 after buying an additional 1,233 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in shares of Bicara Therapeutics by 419.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after buying an additional 3,866 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics in the fourth quarter worth approximately $45,000. Larson Financial Group LLC boosted its holdings in shares of Bicara Therapeutics by 1,015.5% in the third quarter. Larson Financial Group LLC now owns 3,949 shares of the company's stock worth $62,000 after buying an additional 3,595 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Bicara Therapeutics by 385.3% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,775 shares of the company's stock worth $97,000 after buying an additional 4,585 shares during the last quarter.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
